Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:ECIANASDAQ:NEPHNASDAQ:NRXSNASDAQ:VVOS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeECIAEncision$0.37+7.6%$0.38$0.16▼$0.50$4.04M0.54584 shs400 shsNEPHNephros$4.16-3.0%$2.70$1.36▼$5.00$45.48M0.9616,615 shs39,552 shsNRXSNeurAxis$2.44+3.0%$2.45$1.33▼$6.20$17.61M3.34416,954 shs84,175 shsVVOSVivos Therapeutics$2.97+1.0%$2.48$1.97▼$6.28$17.32M7.02464,201 shs230,468 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceECIAEncision+7.65%+13.45%+4.57%-23.43%-12.84%NEPHNephros-3.03%+10.05%+42.47%+160.00%+97.16%NRXSNeurAxis+2.95%-3.56%-19.47%+14.02%-4.69%VVOSVivos Therapeutics+1.02%+37.50%+30.26%-7.19%+38.14%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationECIAEncisionN/AN/AN/AN/AN/AN/AN/AN/ANEPHNephros1.3229 of 5 stars2.53.00.00.02.70.80.0NRXSNeurAxis2.5695 of 5 stars3.53.00.00.01.53.30.0VVOSVivos Therapeutics1.6291 of 5 stars3.32.00.00.02.20.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceECIAEncision 0.00N/AN/AN/ANEPHNephros 3.00Buy$5.0020.19% UpsideNRXSNeurAxis 3.00Buy$7.00186.89% UpsideVVOSVivos Therapeutics 2.50Moderate Buy$4.8262.18% UpsideCurrent Analyst Ratings BreakdownLatest ECIA, NEPH, NRXS, and VVOS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/16/2025NRXSNeurAxisCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy6/16/2025NRXSNeurAxisCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy$7.005/20/2025VVOSVivos TherapeuticsIndustrial Alliance SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$2.255/20/2025VVOSVivos TherapeuticsAlliance Global PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral4/15/2025VVOSVivos TherapeuticsAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$6.60 ➝ $6.204/1/2025VVOSVivos TherapeuticsAlliance Global PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy(Data available from 6/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookECIAEncision$6.59M0.66N/AN/A$0.15 per share2.44NEPHNephros$14.16M3.11$0.02 per share214.38$0.81 per share5.14NRXSNeurAxis$2.93M6.00N/AN/A($0.27) per share-9.04VVOSVivos Therapeutics$15.03M1.16N/AN/A$1.35 per share2.20Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateECIAEncision-$690K-$0.04N/A∞N/A-8.96%-32.90%-15.51%7/14/2025 (Estimated)NEPHNephros$70K$0.0759.44∞N/A5.16%9.43%7.20%8/6/2025 (Estimated)NRXSNeurAxis-$14.63M-$1.19N/A∞N/A-492.76%N/A-641.25%N/AVVOSVivos Therapeutics-$11.14M-$1.73N/AN/AN/A-76.82%-170.43%-77.82%8/13/2025 (Estimated)Latest ECIA, NEPH, NRXS, and VVOS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025NEPHNephros-$0.0050$0.0526+$0.0576$0.05$3.67 million$4.88 million5/15/2025Q1 2025VVOSVivos Therapeutics-$0.44-$0.45-$0.01-$0.45$3.63 million$3.70 million3/27/2025Q4 2024VVOSVivos Therapeutics-$0.43-$0.28+$0.15-$0.28$3.89 million$3.70 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthECIAEncisionN/AN/AN/AN/AN/ANEPHNephrosN/AN/AN/AN/AN/ANRXSNeurAxisN/AN/AN/AN/AN/AVVOSVivos TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioECIAEncision0.111.670.82NEPHNephrosN/A5.924.64NRXSNeurAxisN/A0.240.23VVOSVivos TherapeuticsN/A0.770.77Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipECIAEncision8.20%NEPHNephros41.10%NRXSNeurAxis11.77%VVOSVivos Therapeutics26.35%Insider OwnershipCompanyInsider OwnershipECIAEncision36.75%NEPHNephros6.70%NRXSNeurAxis26.40%VVOSVivos Therapeutics3.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableECIAEncision3011.88 million7.51 millionNot OptionableNEPHNephros3010.60 million9.89 millionNot OptionableNRXSNeurAxis197.22 million6.09 millionNot OptionableVVOSVivos Therapeutics1605.89 million5.71 millionOptionableECIA, NEPH, NRXS, and VVOS HeadlinesRecent News About These CompaniesShort Interest in Vivos Therapeutics, Inc. (NASDAQ:VVOS) Grows By 48.3%June 18, 2025 | americanbankingnews.comVivos Therapeutics, Inc: Vivos Therapeutics Completes Acquisition of The Sleep Center of NevadaJune 11, 2025 | finanznachrichten.deVivos Therapeutics Completes Acquisition of The Sleep Center of NevadaJune 11, 2025 | finance.yahoo.comVivos Therapeutics Completes Acquisition of The Sleep Center of Nevada, Expanding OSA Diagnostic and Treatment CapabilitiesJune 11, 2025 | quiverquant.comVivos Therapeutics Secures $1.1M Convertible NoteMay 23, 2025 | tipranks.comEarnings call transcript: Vivos Therapeutics reports Q1 2025 earnings, stock risesMay 17, 2025 | uk.investing.comVivos Therapeutics, Inc: Vivos Therapeutics Reports First Quarter 2025 Financial Results and Provides Operational UpdateMay 17, 2025 | finanznachrichten.deVivos Therapeutics Inc (VVOS) Q1 2025 Earnings Call Highlights: Strategic Acquisitions and FDA ...May 17, 2025 | finance.yahoo.comVivos Therapeutics’ Earnings Call: Strategic Shifts Amid Financial ChallengesMay 16, 2025 | tipranks.comVivos Therapeutics, Inc. (VVOS) Q1 2025 Earnings Call TranscriptMay 15, 2025 | seekingalpha.comVivos Therapeutics, Inc. (VVOS) Reports Q1 Loss, Lags Revenue EstimatesMay 15, 2025 | zacks.comVivos Therapeutics Reports First Quarter 2025 Financial Results and Provides Operational UpdateMay 15, 2025 | finance.yahoo.comVivos Therapeutics Schedules Release of First Quarter 2025 Financial Results and Conference CallMay 15, 2025 | finance.yahoo.comVivos Therapeutics, Inc. to Release First Quarter 2025 Financial Results on May 15, 2025May 14, 2025 | quiverquant.comVivos Therapeutics Schedules Release of First Quarter 2025 Financial Results and Conference CallMay 14, 2025 | globenewswire.comVivos Therapeutics, Inc. (VVOS) May Report Negative Earnings: Know the Trend Ahead of Q1 ReleaseMay 6, 2025 | zacks.comVivos to acquire sleep centerApril 17, 2025 | hmenews.comVivos Therapeutics announces agreement to acquire operating assets of SCNApril 17, 2025 | markets.businessinsider.comVivos Opens New Sleep CenterApril 16, 2025 | baystreet.caVivos Therapeutics Signs Definitive Agreement to Acquire Largest Sleep Center Operator in NevadaApril 16, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden Dome3 Overlooked Dividend Plays for Income in Volatile TimesBy Nathan Reiff | May 31, 2025View 3 Overlooked Dividend Plays for Income in Volatile TimesTaiwan Semiconductor: Time to Buy After Strong NVIDIA Results?By Gabriel Osorio-Mazilli | May 30, 2025View Taiwan Semiconductor: Time to Buy After Strong NVIDIA Results?U.S. Steel Stock Burns the Bears With Surprise Upside MoveBy Gabriel Osorio-Mazilli | June 17, 2025View U.S. Steel Stock Burns the Bears With Surprise Upside MoveECIA, NEPH, NRXS, and VVOS Company DescriptionsEncision OTCMKTS:ECIA$0.37 +0.03 (+7.65%) As of 06/24/2025 11:40 AM EasternEncision Inc., a medical device company, designs, develops, manufactures, and markets patented surgical instruments in the United States. The company provides active electrode monitoring (AEM) surgical instruments and monitors that enhance patient safety and patient outcomes in laparoscopic surgical procedures. Its AEM instruments product line comprises a range of endo-mechanical instruments, including scissors, graspers, and dissectors, as well as fixed-tip electrodes and suction-irrigation electrodes. The company also offers various handles, which are used for advanced laparoscopic procedures that incorporate stiffer shafts and ergonomic features; and AEM EndoShield 2 burn protection systems, as well as markets AEM monitor product line that is used in conjunction with AEM instruments. The company sells its products through a network of direct and independent sales representatives. Encision Inc. was incorporated in 1991 and is based in Boulder, Colorado.Nephros NASDAQ:NEPH$4.16 -0.13 (-3.03%) Closing price 06/24/2025 04:00 PM EasternExtended Trading$4.56 +0.40 (+9.62%) As of 06/24/2025 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Nephros, Inc., a commercial-stage company, develops and sells water solutions to the medical and commercial markets in the United States. It offers ultrafiltration products that are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities. The company also manufactures and sells water filters that enhance the taste and odor of water, as well as reduce biofilm, cysts, particulates, and scale build-up in downstream equipment. It markets its products to food service, hospitality, convenience store, and health care markets, as well as medical institutions. The company was incorporated in 1997 and is headquartered in South Orange, New Jersey.NeurAxis NASDAQ:NRXS$2.44 +0.07 (+2.95%) Closing price 06/24/2025 04:00 PM EasternExtended Trading$2.44 +0.00 (+0.20%) As of 04:31 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.NeurAxis, Inc., a medical technology company, focuses on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 11-18 years of age with functional abdominal pain associated with irritable bowel syndrome. The company sells its products to healthcare companies, including hospitals and clinics. The company was formerly known as Innovative Health Solutions, Inc. and changed its name to NeurAxis, Inc. in March 2022. The company was founded in 2011 and is headquartered in Carmel, Indiana.Vivos Therapeutics NASDAQ:VVOS$2.97 +0.03 (+1.02%) Closing price 06/24/2025 04:00 PM EasternExtended Trading$2.97 0.00 (0.00%) As of 06/24/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2016 and is based in Littleton, Colorado. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 3 Hot Trades for Insiders, But Are They Good Buys for Investors? Why Qualcomm’s Latest Price Target Can't Be Ignored Texas Instruments Stock: Congress Likes It, Should You Too? Geospace Stock Skyrockets After Major Petrobras Contract Analyst Sees Meta Hitting $800: What May Lead Shares to New Highs CrowdStrike Eyes Breakout as Cyber Threats Boost Demand Reddit Stock Ignites: Surge in Call Options Signals Big Bet Microsoft Stock Holds Steady as AI Drives Workforce Shift Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
